Evonik stock gets a Berenberg upgrade to Hold on October 5, 2026

Published on 10/05/2026 at 22:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Evonik stock carries a EUR 20.00 Berenberg target after the October 5 upgrade from Sell to Hold. Q2 adjusted EBITDA rose 24 percent to EUR 630 million.

Geometrisches Bauhaus-Poster mit fettem Text CHEMIE in Primärfarben Rot Gelb Blau nach 1920er Stil — Evonik Industries DE000EVNK013 als geometrisches Bauhaus-Poster mit dem Sektor-Text CHEMIE in leuchtenden Primärfarben, Illustration mit AI erstellt.

Evonik (ISIN DE000EVNK013) was last at EUR 20.70 on Xetra on October 5, 2026, leaving the stock 1.62 percent below its 52-week high of EUR 21.04. The immediate catalyst was Berenberg's upgrade from Sell to Hold and its increase of the price target to EUR 20.00 from EUR 15.50, as Investing.com reported on October 5, 2026.

Berenberg changes its stance

The move shifts Berenberg's published view by two steps, from Sell to Hold, while the target rises EUR 4.50. The price target lies 3.38 percent below the Xetra price of EUR 20.70, so the revised target itself does not imply further upside from the latest quote.

Markets Insider also reported on October 5, 2026, that analyst Sebastian Bray set the target at EUR 20.00. The report linked the more constructive stance to BASF's interest in a possible takeover and to the prospect that the approach could support Evonik's share price.

Q2 earnings support the case

Evonik's second-quarter operating picture provides a separate reference point. Adjusted EBITDA rose 24 percent year over year to EUR 630 million in Q2 2026, according to the Yahoo Finance transcript published on September 18, 2026. Management said first-half adjusted EBITDA reached EUR 1.1 billion and maintained a full-year outlook centered on another EUR 1.0 billion in the second half.

The improvement came with an important qualification. The earnings call attributed the stronger quarter to higher volumes and prices, while market conditions affecting Asian competitors supported parts of the portfolio. Berenberg also noted that methionine prices had started to fall, making the durability of the current earnings boost a central issue for the stock.

Restructuring adds a second track

Evonik is pairing the earnings recovery with a cost program. In its September 22 strategy release, the company said the second phase of its Tailor Made restructuring will run from 2027 through 2029 and include 3,200 job cuts worldwide, including 2,150 in Germany, as reported by Evonik. The company said the savings are intended to create room for investments in growth markets.

For investors, the valuation discussion now sits between a takeover possibility and the quality of recurring earnings. The market capitalization was EUR 9.6 billion on October 5, 2026, while trading volume reached 1,122,246 shares and the 52-week range stood at EUR 12.49 to EUR 21.04.

Evonik stock stays near its yearly high

Evonik stock was last at EUR 20.70 on Xetra on October 5, 2026 at 5:35 p.m. CEST, with a daily change of 0.29 percent. The quote remains 1.62 percent below the 52-week high, keeping the takeover debate and the durability of Q2 earnings at the center of the valuation.